Inozyme Pharma Reports Promising Interim Results from Phase 1 SEAPORT 1 Trial of INZ-701

Inozyme Pharma, Inc., a biopharma company focused on pioneering treatments for rare diseases impacting bone and vascular health, has reported encouraging interim results from its Phase 1 SEAPORT 1 trial of INZ-701. The study, targeting patients with end-stage kidney disease (ESKD) on hemodialysis, will be presented at the American Society of Nephrology’s Kidney Week 2024, running from October 24-27 in San Diego.

Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma, said in a statement, “The interim data from the SEAPORT 1 trial demonstrate that INZ-701 significantly raised PPi levels in patients with end-stage kidney disease and was well-tolerated in this high-risk population. Low PPi levels are linked to the development of calciphylaxis, a rare and life-threatening complication of end-stage kidney disease, as well as the associated morbidity and mortality. Pending alignment with regulatory authorities and sufficient funding, these encouraging results provide a strong foundation for advancing INZ-701 into a registrational trial in calciphylaxis.”

Sagar Nigwekar, MD, MMSc, Co-Director, Kidney Research Center, Massachusetts General Hospital, further explained, "Calciphylaxis represents one of the most challenging complications of end-stage kidney disease, with profound impacts on patient quality of life and survival. The interim results from the SEAPORT 1 trial are encouraging, showing that INZ-701 elevated PPi levels in patients with end-stage kidney disease. PPi levels are critically deficient in patients with calciphylaxis and by addressing this underlying deficiency, INZ-701 has the potential to modify the course of this disease and offer hope where no approved therapies currently exist.”